{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:01:44Z","timestamp":1785801704881,"version":"3.56.0"},"reference-count":13,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J NeuroIntervent Surg"],"accepted":{"date-parts":[[2023,6,11]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Melphalan, which is poorly soluble at room temperature, is widely used for the treatment of retinoblastoma by selective ophthalmic artery infusion. Evomela, a propylene glycol-free formulation of melphalan with improved solubility and stability, has recently been used as an alternative.<\/jats:p>\n                  <jats:p>To compare the safety and efficacy of Evomela with standard-formulation melphalan (SFM) in the treatment of retinoblastoma by selective ophthalmic artery infusion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a retrospective case\u2013control study of patients with retinoblastoma undergoing selective ophthalmic artery infusion with SFM or Evomela at a single institution. Cycle-specific percent tumor regression (CSPTR) was estimated by comparing photos obtained during pretreatment examination under anesthesia (EUA) with those obtained during post-treatment EUA 3\u20134 weeks later. CSPTR, ocular salvage rates, complication rates, operation times (unadjusted and adjusted for difficulty of ophthalmic artery catheterization), and intraprocedural dose expiration rates were compared between Evomela- and SFM-treated groups. Univariate and multivariate analyses were performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ninety-seven operations (melphalan: 45; Evomela: 52) for 23 patients with 27 retinoblastomas were studied. The ocular salvage rate was 79% in the SFM-treated group and 69% in the Evomela-treated group. Multivariate regression controlling for tumor grade, patient age, and treatment history revealed no significant differences in ocular salvage rate, CSPTR, complication rates, or operation times. Although the dose expiration rate was higher for the SFM-treated group, the difference was not statistically significant. Notably, there were no ocular or cerebral ischemic complications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Evomela has non-inferior safety and efficacy relative to SFM when used for the treatment of retinoblastoma by selective ophthalmic artery infusion.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jnis-2023-020170","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T13:20:19Z","timestamp":1687958419000},"page":"572-577","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of a prolonged stability melphalan formulation for intra-arterial treatment of retinoblastoma"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2517-4563","authenticated-orcid":false,"given":"Jubran H","family":"Jubran","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3498-4488","authenticated-orcid":false,"given":"Hanna","family":"Luong","sequence":"additional","affiliation":[{"name":"Department of Pediatric Ophthalmology, Retinoblastoma Division, Phoenix Children's Hospital, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Naik","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7673-6805","authenticated-orcid":false,"given":"Visish M","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Ramasubramanian","sequence":"additional","affiliation":[{"name":"Department of Pediatric Ophthalmology, Retinoblastoma Division, Phoenix Children's Hospital, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Phoenix Children's Hospital, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Scherschinski","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8979-3128","authenticated-orcid":false,"given":"Michael J","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3251-1086","authenticated-orcid":false,"given":"Felipe C","family":"Albuquerque","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A","family":"Abruzzo","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona, USA"},{"name":"Department of Pediatric Ophthalmology, Retinoblastoma Division, Phoenix Children's Hospital, Phoenix, Arizona, USA"},{"name":"Department of Radiology, Phoenix Children's Hospital, Phoenix, AZ, USA"},{"name":"University of Arizona College of Medicine - Phoenix, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,6,28]]},"reference":[{"key":"2025092912091562000_16.6.572.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.07.025"},{"key":"2025092912091562000_16.6.572.2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000471"},{"key":"2025092912091562000_16.6.572.3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145436","article-title":"Advanced unilateral retinoblastoma: the impact of ophthalmic artery chemosurgery on enucleation rate and patient survival at MSKCC","volume":"10","author":"Abramson","year":"2015","journal-title":"PLoS One"},{"key":"2025092912091562000_16.6.572.4","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.oret.2021.05.007","article-title":"Selective ophthalmic artery chemotherapy with melphalan in the management of unilateral retinoblastoma: a prospective study","volume":"5","author":"Lumbroso-Le Rouic","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"2025092912091562000_16.6.572.5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40268-015-0098-4","article-title":"Stability of melphalan in 0.9% sodium chloride solutions prepared in polyvinyl chloride bags for intravenous injection","volume":"15","author":"Desmaris","year":"2015","journal-title":"Drugs R D"},{"key":"2025092912091562000_16.6.572.6","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1080\/10837450.2016.1265557","article-title":"Solution stability of captisol-stabilized melphalan (Evomela) versus propylene glycol-based melphalan hydrochloride injection","volume":"23","author":"Singh","year":"2018","journal-title":"Pharm Dev Technol"},{"key":"2025092912091562000_16.6.572.7","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2019-014909"},{"key":"2025092912091562000_16.6.572.8","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3156503","article-title":"The safety and effectiveness of melphalan-based intra-arterial chemotherapy for retinoblastoma: an updated single-arm systematic review and meta-analysis","volume":"2022","author":"Cao","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"key":"2025092912091562000_16.6.572.9","doi-asserted-by":"crossref","first-page":"108439","DOI":"10.1016\/j.exer.2021.108439","article-title":"Intravitreal melphalan hydrochloride vs propylene glycol-free melphalan for retinoblastoma vitreous seeds: efficacy, toxicity and stability in rabbits models and patients","volume":"204","author":"Bogan","year":"2021","journal-title":"Exp Eye Res"},{"key":"2025092912091562000_16.6.572.10","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A6905"},{"key":"2025092912091562000_16.6.572.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.08.045"},{"key":"2025092912091562000_16.6.572.12","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.151"},{"key":"2025092912091562000_16.6.572.13","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaophthalmol.2014.2324","article-title":"Stability of melphalan solution for intravitreal injection for retinoblastoma","volume":"132","author":"Buitrago","year":"2014","journal-title":"JAMA Ophthalmol"}],"container-title":["Journal of NeuroInterventional Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnis-2023-020170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:09:22Z","timestamp":1759172962000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnis.bmj.com\/lookup\/doi\/10.1136\/jnis-2023-020170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,28]]},"references-count":13,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,21]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/jnis-2023-020170"],"URL":"https:\/\/doi.org\/10.1136\/jnis-2023-020170","relation":{},"ISSN":["1759-8478","1759-8486"],"issn-type":[{"value":"1759-8478","type":"print"},{"value":"1759-8486","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,28]]}}}